Drug intelligence / Profile preview

cefazolin + ketorolac + pantoprazole + paracetamol

Development stage
Unknown
Lead developer
Hospital da Luz
Modality
Small Molecules
Administration
Intravenous
01

Overview

This standardized perioperative medication regimen is utilized by Hospital da Luz, Portugal, as a baseline treatment for patients undergoing orthopedic surgery with neuraxial anesthesia. The combination therapy consists of four distinct pharmaceutical agents: cefazolin, a first-generation cephalosporin antibiotic used for surgical site infection prophylaxis; ketorolac, a potent non-steroidal anti-inflammatory drug (NSAID) for acute pain management; pantoprazole, a proton pump inhibitor (PPI) administered to prevent stress-induced gastric ulcers and reduce acid secretion; and paracetamol, a non-opioid analgesic and antipyretic. In the context of clinical research (NCT04441411), this regimen is administered to all study participants to ensure a consistent baseline of care while evaluating the comparative effects of midazolam versus propofol sedation on core temperature variations.

Other names
Standard medication regimen (Hospital da Luz)Standard treatment (NCT04441411)
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PBP (Penicillin-binding protein family)ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on cefazolin + ketorolac + pantoprazole + paracetamol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cefazolin + ketorolac + pantoprazole + paracetamol.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call